Rocket One Inc. (RKTO)

NASDAQ:RKTO

RKTO

Rocket One

RESEARCH TOOLSreports

Rocket One (RKTO) Price & Analysis

504 Followers

RKTO Stock Chart & Stats

$1.20

-$0.38(-16.67%)

At close: Jan 08 4:00 PM EST

$1.20

-$0.38(-16.67%)

Day’s Range― - ―

52-Week Range$0.49 - $2.45

Previous Close$2.09

VolumeN/A

Average Volume (3M)12.47M

Market Cap

$41.41M

Enterprise Value$23.88M

Total Cash (Recent Filing)$4.05M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta-0.12

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.81

Shares Outstanding21,022,497

10 Day Avg. Volume35,753,046

30 Day Avg. Volume12,470,127

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)2.22

Price to Sales (P/S)0.00

P/FCF Ratio-1.39

Enterprise Value/Market Cap0.58

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-2.07

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.59

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe open-label portion of HT-001 trial yields promising results, with 100% of patients achieving the primary efficacy endpoint, showing significant skin toxicity improvement.

Market OpportunitiesThe obesity market represents a large commercial opportunity, with favorable early results potentially constituting a substantial value inflection point.

PartnershipsThe company has entered into an exclusive patent license agreement with the U.S. Department of Veterans Affairs, providing rights to a groundbreaking innovation aimed at treating obesity and associated health conditions.

Bears Say

Intellectual PropertyAdvancements in intellectual property may provide the ability to secure market exclusivity for additional indications addressable with HT-001, Hoth's most advanced asset.

Rocket One News

Rocket One Expands At-The-Market Stock Offering Capacity

Rocket One ( ($RKTO) ) has issued an update. On June 3, 2026, Rocket One Inc. increased the...

3d ago

RKTO

Rocket One Adds Defense Leader to Advisory Board

An update from Rocket One ( ($RKTO) ) is now available. On June 3, 2026, Rocket One Inc....

3d ago

RKTO

RKTO FAQ

What was Rocket One Inc.’s price range in the past 12 months?

Rocket One Inc. lowest stock price was $0.49 and its highest was $2.45 in the past 12 months.

What is Rocket One Inc.’s market cap?

Rocket One Inc.’s market cap is $41.41M.

When is Rocket One Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Rocket One Inc.’s earnings last quarter?

Currently, no data Available

Is Rocket One Inc. overvalued?

According to Wall Street analysts Rocket One Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Rocket One Inc. pay dividends?

Rocket One Inc. does not currently pay dividends.

What is Rocket One Inc.’s EPS estimate?

Rocket One Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Rocket One Inc. have?

Rocket One Inc. has 21,022,497 shares outstanding.

What happened to Rocket One Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Rocket One Inc.?

Currently, no hedge funds are holding shares in RKTO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Rocket One Stock Smart Score

Neutral

Fundamentals

Return on Equity

-165.25%

Trailing 12-Months

Asset Growth

-54.72%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Rocket One Inc.

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in Hoboken, NJ.